CoChat
Sign Up
Cited by 355

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

Guertin, David A., Stevens, Deanna M., Saitoh, Maki, Kinkel, Stephanie, Crosby, Katherine, Sheen, Joon-Ho, Mullholland, David J., Magnuson, Mark A., Wu, Hong, Sabatini, David M.·2009·Cancer Cell
DOI 10.1016/j.ccr.2008.12.017PMC PMC2701381
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2008.12.017

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 53

  1. Abraham, 2008, Mammalian target of rapamycin as a therapeutic target in oncology, Expert Opin. Ther. Targets, 12, 209, 10.1517/14728222.12.2.209 · DOI
  2. Alessi, 1996, Mechanism of activation of protein kinase B by insulin and IGF-1, EMBO J., 15, 6541, 10.1002/j.1460-2075.1996.tb01045.x · DOI
  3. Backman, 2001, Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease, Nat. Genet., 29, 396, 10.1038/ng782 · DOI
  4. Bayascas, 2005, Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/−) mice, Curr. Biol., 15, 1839, 10.1016/j.cub.2005.08.066 · DOI
  5. Bhaskar, 2007, The two TORCs and Akt, Dev. Cell, 12, 487, 10.1016/j.devcel.2007.03.020 · DOI · Paper page
  6. Biondi, 2001, The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB, EMBO J., 20, 4380, 10.1093/emboj/20.16.4380 · DOI · Paper page
  7. Bjornsti, 2004, The TOR pathway: a target for cancer therapy, Nat. Rev. Cancer, 4, 335, 10.1038/nrc1362 · DOI
  8. Bozulic, 2008, PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival, Mol. Cell, 30, 203, 10.1016/j.molcel.2008.02.024 · DOI
  9. Chen, 2006, The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/− mice, Genes Dev., 20, 1569, 10.1101/gad.1395006 · DOI
  10. Chiang, 2007, Targeting the mTOR signaling network in cancer, Trends Mol. Med., 13, 433, 10.1016/j.molmed.2007.08.001 · DOI
  11. Collins, 2003, In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation, EMBO J., 22, 4202, 10.1093/emboj/cdg407 · DOI
  12. Dahia, 2000, PTEN, a unique tumor suppressor gene, Endocr. Relat. Cancer, 7, 115, 10.1677/erc.0.0070115 · DOI
  13. Di Cristofano, 1998, Pten is essential for embryonic development and tumour suppression, Nat. Genet., 19, 348, 10.1038/1235 · DOI
  14. Facchinetti, 2008, The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C, EMBO J., 27, 1932, 10.1038/emboj.2008.120 · DOI
  15. Freeman, 2006, Genetic background controls tumor development in PTEN-deficient mice, Cancer Res., 66, 6492, 10.1158/0008-5472.CAN-05-4143 · DOI
  16. Frias, 2006, mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s, Curr. Biol., 16, 1865, 10.1016/j.cub.2006.08.001 · DOI
  17. Garcia-Martinez, 2008, mTOR complex-2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum and glucocorticoid induced protein kinase-1 (SGK1), Biochem. J., 416, 375, 10.1042/BJ20081668 · DOI · Paper page
  18. Guertin, 2007, Defining the Role of mTOR in Cancer, Cancer Cell, 12, 9, 10.1016/j.ccr.2007.05.008 · DOI · Paper page
  19. Guertin, 2006, Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1, Dev. Cell, 11, 859, 10.1016/j.devcel.2006.10.007 · DOI
  20. Hanada, 2004, Structure, regulation and function of PKB/AKT--a major therapeutic target, Biochim. Biophys. Acta, 1697, 3, 10.1016/j.bbapap.2003.11.009 · DOI
  21. Hietakangas, 2007, Re-evaluating AKT regulation: role of TOR complex 2 in tissue growth, Genes Dev., 21, 632, 10.1101/gad.416307 · DOI
  22. Hresko, 2005, mTOR/RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes, J. Biol. Chem., 280, 40406, 10.1074/jbc.M508361200 · DOI
  23. Huang, 2005, Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis, Acta Pharmacol. Sin., 26, 1253, 10.1111/j.1745-7254.2005.00184.x · DOI
  24. Ikenoue, 2008, Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling, EMBO J., 27, 1919, 10.1038/emboj.2008.119 · DOI
  25. Jacinto, 2006, SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity, Cell, 127, 125, 10.1016/j.cell.2006.08.033 · DOI
  26. Jiao, 2007, Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development, Cancer Res., 67, 6083, 10.1158/0008-5472.CAN-06-4202 · DOI
  27. Kim, 2002, mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery, Cell, 110, 163, 10.1016/S0092-8674(02)00808-5 · DOI
  28. Kovacina, 2003, Identification of a proline-rich Akt substrate as a 14-3-3 binding partner, J. Biol. Chem., 278, 10189, 10.1074/jbc.M210837200 · DOI
  29. Kumar, 2008, Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances basal glycogen synthase activity, Mol. Cell. Biol., 28, 61, 10.1128/MCB.01405-07 · DOI
  30. Lee, 2005, TOR complex 2 integrates cell movement during chemotaxis and signal relay in Dictyostelium, Mol. Biol. Cell, 16, 4572, 10.1091/mbc.e05-04-0342 · DOI
  31. Lei, 2006, NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss, Cancer Cell, 9, 367, 10.1016/j.ccr.2006.03.031 · DOI
  32. Manning, 2004, Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis, J. Cell Biol., 167, 399, 10.1083/jcb.200408161 · DOI
  33. Manning, 2007, AKT/PKB signaling: navigating downstream, Cell, 129, 1261, 10.1016/j.cell.2007.06.009 · DOI · Paper page
  34. Masri, 2007, mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor, Cancer Res., 67, 11712, 10.1158/0008-5472.CAN-07-2223 · DOI
  35. Phung, 2006, Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin, Cancer Cell, 10, 159, 10.1016/j.ccr.2006.07.003 · DOI
  36. Podsypanina, 1999, Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems, Proc. Natl. Acad. Sci. USA, 96, 1563, 10.1073/pnas.96.4.1563 · DOI
  37. Rowinsky, 2004, Targeting the molecular target of rapamycin (mTOR), Curr. Opin. Oncol., 16, 564, 10.1097/01.cco.0000143964.74936.d1 · DOI
  38. Salmena, 2008, Tenets of PTEN tumor suppression, Cell, 133, 403, 10.1016/j.cell.2008.04.013 · DOI
  39. Sarbassov, 2004, Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton, Curr. Biol., 14, 1296, 10.1016/j.cub.2004.06.054 · DOI · Paper page
  40. Sarbassov, 2006, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB, Mol. Cell, 22, 159, 10.1016/j.molcel.2006.03.029 · DOI · Paper page
  41. Shiota, 2006, Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability, Dev. Cell, 11, 583, 10.1016/j.devcel.2006.08.013 · DOI
  42. Shor, 2008, A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis, Cancer Res., 68, 2934, 10.1158/0008-5472.CAN-07-6487 · DOI
  43. Skeen, 2006, Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner, Cancer Cell, 10, 269, 10.1016/j.ccr.2006.08.022 · DOI
  44. Suzuki, 1998, High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice, Curr. Biol., 8, 1169, 10.1016/S0960-9822(07)00488-5 · DOI
  45. Suzuki, 1998, Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues, Cancer Res., 58, 204
  46. Tessier, 2006, Serum and glucocorticoid-regulated protein kinases: variations on a theme, J. Cell. Biochem., 98, 1391, 10.1002/jcb.20894 · DOI
  47. Trotman, 2003, Pten dose dictates cancer progression in the prostate, PLoS Biol., 1, E59, 10.1371/journal.pbio.0000059 · DOI
  48. Vander Haar, 2007, Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40, Nat. Cell Biol., 9, 316, 10.1038/ncb1547 · DOI
  49. Vignot, 2005, mTOR-targeted therapy of cancer with rapamycin derivatives, Ann. Oncol., 16, 525, 10.1093/annonc/mdi113 · DOI
  50. Wang, 2003, Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer, Cancer Cell, 4, 209, 10.1016/S1535-6108(03)00215-0 · DOI · Paper page
  51. Wu, 2001, Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation, Mech. Dev., 101, 61, 10.1016/S0925-4773(00)00551-7 · DOI
  52. Yang, 2006, Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity, Genes Dev., 20, 2820, 10.1101/gad.1461206 · DOI
  53. Zeng, 2006, Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML, Blood, 109, 3509, 10.1182/blood-2006-06-030833 · DOI

Cited by

Sorted by citations

See all 355

Metadata

Authors
Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H., & Sabatini, D. M.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2009-02
Volume
15
Issue
2
Pages
148-159
ISSN
1535-6108
DOI
10.1016/j.ccr.2008.12.017
PMC
PMC2701381
Cited by
355
References
2
Language
en
Licence
Funders
  • Howard Hughes Medical Institute
  • W. M. Keck Foundation
  • Damon Runyon Cancer Research Foundation
  • Leukemia and Lymphoma Society
  • National Institutes of Health (K99 CA1296613-01A1, R01 AI04389, R01 CA103866, R01 CA107166)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review